Avanir, Wockhardt neurology news

Avanir and Wockhardt settled a 2011 suit alleging Wockhardt's ANDA for a generic version of Nuedexta dextromethorphan/quinidine to treat pseudobulbar affect (PBA) infringes Avanir's U.S. Patent Nos. 7,659,282 and RE38,115. Under the settlement, Wockhardt received rights to begin selling its generic version on July 30, 2026, or earlier under undisclosed criteria. PBA is characterized by involuntary episodes of laughing and/or crying. ...